Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07843550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

Name: A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy — clinical trial record (NCT07843550)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorM.D. Anderson Cancer Center

Started2027-03-01

View on ClinicalTrials.gov ↗

M.D. Anderson Cancer Center

1,223 trials monitored

See 78 trials at risk

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.

Trial Details

NCT Number	NCT07843550
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Solid Tumor
Enrollment	22 participants
Start Date	2027-03-01
Primary Completion	2027-07-13 (estimated)
Study Completion	2029-07-13 (estimated)
Updated on ClinicalTrials.gov	2026-09-28